Navigation Links
EntreMed Secures $10 Million Strategic Financing
Date:1/23/2012

rants are not exercisable, prior to receiving stockholder approval.  If stockholder approval is not obtained, the Company will be required to pay liquidated damages to the note purchasers equal to an aggregate of $1.2 million.

"We are very pleased to have the support from a group of knowledgeable investors and the validation of the potential of ENMD-2076. The proceeds from the notes will allow the Company to accelerate and expand its research and development activities, fund additional trials, initiatives and long term strategic plans," said Michael M. Tarnow, the Company's Executive Chairman.

After deducting transaction fees and expenses, the net proceeds to the Company will be approximately $9.3 million.  The convertible notes, the warrants and the common stock into which the notes and warrants are convertible have not been registered under the Securities Act of 1933, as amended (the "Act") and applicable state securities laws, but have been offered and sold in the United States pursuant to applicable exemptions from registration requirements under the Act and applicable state securities laws. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important rol
'/>"/>

SOURCE EntreMed
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAS VEGAS , July 30, 2014  DigiPath, ... provider that is expanding into the cannabis testing and ... development in its business and affairs not previously disclosed ... for the recent unusual market action. "We ... securities over the last three trading days," said ...
(Date:7/30/2014)... , July 30, 2014 /PRNewswire-iReach/ -- This ... Global and Chinese Heparin sodium (CAS 9041-08-1) & ... the basic information of Heparin sodium (CAS 9041-08-1) ... and manufacturing technology. The report then explores global ... 9041-08-1) & calcium (CAS 37270-89-6) listing their product ...
(Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. ... company management will participate in the Jefferies 2014 Boston ... , Massachusetts. The conference will occur on August 6, 2014 ... BioPharma, Inc. PDL BioPharma manages a portfolio ... Queen et al. antibody humanization patents and license agreements ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
(Date:7/30/2014)... 2014 Today, Gen. Arthur T. Dean, ... America (CADCA) , the nation’s leading substance abuse prevention ... New York Times Editorial Board’s call for ... , “CADCA is disappointed in the New York ... national marijuana legalization. The move is shortsighted and completely ...
(Date:7/30/2014)... 30, 2014 (HealthDay News) -- Clues to whether a person ... blood test, a new study suggests. Chemical changes to ... may help spur suicidal thoughts and behaviors, the study,s authors ... alert doctors to a patient,s risk for suicide, they said. ... we have been stymied in our prevention efforts because we ...
(Date:7/30/2014)... Scientists in Manchester have identified a protein that could ... from a treatment that makes radiotherapy more effective, according ... of Cancer (BJC). , The team from The ... found that patients whose bladder tumour had high levels ... benefit from having carbogen oxygen mixed with carbon ...
(Date:7/30/2014)... with depression as preschoolers are likely to suffer from ... shows. , Depressed preschoolers were 2.5 times more likely ... school than kids who were not depressed at very ... of Medicine in St. Louis. , Their study is ... Journal of Psychiatry . , "It,s the same old ...
(Date:7/30/2014)... The Europe commercial aviation actuation system market ... is expected to reach $1,686.72 million by 2019 at ... an exclusive range of opportunities and challenges which will ... has seen slumps in the past, yet the sector ... to its long-term growth rate of approximately 5 % ...
Breaking Medicine News(10 mins):Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4
... to donation , , WEDNESDAY, Jan. 28 (HealthDay News) -- Americans ... tend to lead long, healthy lives themselves. , That,s the ... , "Their lifespan is comparable to others of the same ... N. Ibrahim, an associate professor of medicine at the University ...
... (NYSE: NTY ) ( www.NBTY.com ), a leading ... for the fiscal first quarter ended December 31, 2008.For the ... $661 million compared to $511 million for the fiscal first ... or 29%. Included in this total are net sales ...
... at The Medical College of Wisconsin to help prevent ... one of eight chosen by the Centers for Disease ... Compendium of Evidence-based HIV Prevention Interventions. To be included, ... STD-related risk behaviors, or promote safer behaviors. ...
... 28 CCA Industries, Inc. ... that the Board of Directors declared ... the 1st Quarter ending February 28, ... record February 3, 2009 and payable ...
... PRINCETON, N.J., Jan. 28 Covance Inc. (NYSE: ... December 31, 2008 of $0.72 per diluted share. For ... from $2.71 in 2007. Excluding the gain on sale ... share grew 14.5% to $3.03 in 2008 from $2.65 in ...
... PHILADELPHIA, Jan. 28 Leading Philadelphia lawyer Robert Spinelli ... Texas attorney Aaron DeLuca of DeLuca & Nemeroff LLP ... education for attorneys featuring doctors, trial attorneys and judges, ... event, titled "Introduction of General & Specific Causation Evidence ...
Cached Medicine News:Health News:Most Kidney Donors Lead Long, Healthy Lives 2Health News:Most Kidney Donors Lead Long, Healthy Lives 3Health News:NBTY Reports First Quarter Results 2Health News:NBTY Reports First Quarter Results 3Health News:NBTY Reports First Quarter Results 4Health News:NBTY Reports First Quarter Results 5Health News:NBTY Reports First Quarter Results 6Health News:NBTY Reports First Quarter Results 7Health News:NBTY Reports First Quarter Results 8Health News:NBTY Reports First Quarter Results 9Health News:NBTY Reports First Quarter Results 10Health News:NBTY Reports First Quarter Results 11Health News:NBTY Reports First Quarter Results 12Health News:NBTY Reports First Quarter Results 13Health News:NBTY Reports First Quarter Results 14Health News:NBTY Reports First Quarter Results 15Health News:NBTY Reports First Quarter Results 16Health News:Medical College of Wisconsin recognized for AIDS intervention research 2Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 2Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 3Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 4Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 5Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 6Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 7Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 8Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 9Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 10Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 11Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 12Health News:Toxic Causation Training Day for Attorneys 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: